U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C27H44O2.H2O
Molecular Weight 418.6523
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 2
Charge 0

SHOW SMILES / InChI
Structure of CALCIFEDIOL

SMILES

O.[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C3\C[C@@H](O)CCC3=C)[C@H](C)CCCC(C)(C)O

InChI

InChIKey=WRLFSJXJGJBFJQ-WPUCQFJDSA-N
InChI=1S/C27H44O2.H2O/c1-19-10-13-23(28)18-22(19)12-11-21-9-7-17-27(5)24(14-15-25(21)27)20(2)8-6-16-26(3,4)29;/h11-12,20,23-25,28-29H,1,6-10,13-18H2,2-5H3;1H2/b21-11+,22-12-;/t20-,23+,24-,25+,27-;/m1./s1

HIDE SMILES / InChI
Molecular Formula C27H44O2
Molecular Weight 400.6371
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 2
Optical Activity UNSPECIFIED
Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Calcifediol (25-Hydroxyvitamin D3 or 25-hydroxycholecalciferol) is a biologically active vitamin D3 metabolite. It is concluded that the liver is the major if not the only physiologic site of hydroxylation of vitamin D3 into calcifediol. Calcifediol is a prohormone of the active form of vitamin D3, calcitriol (1,25-dihydroxyvitamin D3). Calcifediol is converted to calcitriol by cytochrome P450 27B1 (CYP27B1), also called 1-alpha hydroxylase, primarily in the kidney. Calcitriol binds to the vitamin D receptor in target tissues and activates vitamin D responsive pathways that result in increased intestinal absorption of calcium and phosphorus and reduced parathyroid hormone synthesis. RAYALDEE (calcifediol) extended-release capsules is indicated for the treatment of secondary hyperparathyroidism in adult patients with stage 3 or 4 chronic kidney disease.

CNS Activity

Originator

Approval Year

1980
57
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2678
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
RAYALDEE

Approved Use

Calcifediol indicated for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less than 30 ng/mL

Launch Date

1.46603521E12
Primary
Approved
8429
CALDEROL

Approved Use

Unknown

Launch Date

3.34195196E11
Primary
Approved
8429
CALDEROL

Approved Use

Unknown

Launch Date

3.34195196E11
Primary
Approved
8429
CALDEROL

Approved Use

Unknown

Launch Date

3.34195196E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
73.2 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/24516879/
20 mg 1 times / day steady-state, oral
dose: 20 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CALCIFEDIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1704.4 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/24516879/
20 mg 1 times / day steady-state, oral
dose: 20 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CALCIFEDIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11 day
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/24516879/
20 mg 1 times / day steady-state, oral
dose: 20 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CALCIFEDIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
2%
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/24516879/
20 mg 1 times / day steady-state, oral
dose: 20 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
CALCIFEDIOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FED
Doses

Doses

DosePopulationAdverse events​
30 ug 1 times / day multiple, oral (starting)
Dose: 30 ug, 1 times / day
Route: oral
Route: multiple
Dose: 30 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
unhealthy, 66 years (range: 25-85 years)
n = 285
Health Status: unhealthy
Condition: secondary hyperparathyroidism
Age Group: 66 years (range: 25-85 years)
Sex: M+F
Population Size: 285
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
Other AEs: Anemia, Nasopharyngitis...
Other AEs:
Anemia (4.9%)
Nasopharyngitis (4.9%)
Blood creatinine increased (4.9%)
Dyspnea (4.2%)
Cough (3.5%)
Cardiac failure congestive (3.5%)
Constipation (3.2%)
Bronchitis (2.8%)
Hyperkalemia (2.5%)
Osteoarthritis (2.1%)
Hyperuricemia (1.8%)
Contusion (1.8%)
Pneumonia (1.4%)
Chronic obstructive pulmonary disease (1.4%)
Calcium increased serum (4.2%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Chronic obstructive pulmonary disease 1.4%
30 ug 1 times / day multiple, oral (starting)
Dose: 30 ug, 1 times / day
Route: oral
Route: multiple
Dose: 30 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
unhealthy, 66 years (range: 25-85 years)
n = 285
Health Status: unhealthy
Condition: secondary hyperparathyroidism
Age Group: 66 years (range: 25-85 years)
Sex: M+F
Population Size: 285
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
Pneumonia 1.4%
30 ug 1 times / day multiple, oral (starting)
Dose: 30 ug, 1 times / day
Route: oral
Route: multiple
Dose: 30 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
unhealthy, 66 years (range: 25-85 years)
n = 285
Health Status: unhealthy
Condition: secondary hyperparathyroidism
Age Group: 66 years (range: 25-85 years)
Sex: M+F
Population Size: 285
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
Contusion 1.8%
30 ug 1 times / day multiple, oral (starting)
Dose: 30 ug, 1 times / day
Route: oral
Route: multiple
Dose: 30 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
unhealthy, 66 years (range: 25-85 years)
n = 285
Health Status: unhealthy
Condition: secondary hyperparathyroidism
Age Group: 66 years (range: 25-85 years)
Sex: M+F
Population Size: 285
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
Hyperuricemia 1.8%
30 ug 1 times / day multiple, oral (starting)
Dose: 30 ug, 1 times / day
Route: oral
Route: multiple
Dose: 30 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
unhealthy, 66 years (range: 25-85 years)
n = 285
Health Status: unhealthy
Condition: secondary hyperparathyroidism
Age Group: 66 years (range: 25-85 years)
Sex: M+F
Population Size: 285
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
Osteoarthritis 2.1%
30 ug 1 times / day multiple, oral (starting)
Dose: 30 ug, 1 times / day
Route: oral
Route: multiple
Dose: 30 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
unhealthy, 66 years (range: 25-85 years)
n = 285
Health Status: unhealthy
Condition: secondary hyperparathyroidism
Age Group: 66 years (range: 25-85 years)
Sex: M+F
Population Size: 285
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
Hyperkalemia 2.5%
30 ug 1 times / day multiple, oral (starting)
Dose: 30 ug, 1 times / day
Route: oral
Route: multiple
Dose: 30 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
unhealthy, 66 years (range: 25-85 years)
n = 285
Health Status: unhealthy
Condition: secondary hyperparathyroidism
Age Group: 66 years (range: 25-85 years)
Sex: M+F
Population Size: 285
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
Bronchitis 2.8%
30 ug 1 times / day multiple, oral (starting)
Dose: 30 ug, 1 times / day
Route: oral
Route: multiple
Dose: 30 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
unhealthy, 66 years (range: 25-85 years)
n = 285
Health Status: unhealthy
Condition: secondary hyperparathyroidism
Age Group: 66 years (range: 25-85 years)
Sex: M+F
Population Size: 285
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
Constipation 3.2%
30 ug 1 times / day multiple, oral (starting)
Dose: 30 ug, 1 times / day
Route: oral
Route: multiple
Dose: 30 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
unhealthy, 66 years (range: 25-85 years)
n = 285
Health Status: unhealthy
Condition: secondary hyperparathyroidism
Age Group: 66 years (range: 25-85 years)
Sex: M+F
Population Size: 285
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
Cardiac failure congestive 3.5%
30 ug 1 times / day multiple, oral (starting)
Dose: 30 ug, 1 times / day
Route: oral
Route: multiple
Dose: 30 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
unhealthy, 66 years (range: 25-85 years)
n = 285
Health Status: unhealthy
Condition: secondary hyperparathyroidism
Age Group: 66 years (range: 25-85 years)
Sex: M+F
Population Size: 285
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
Cough 3.5%
30 ug 1 times / day multiple, oral (starting)
Dose: 30 ug, 1 times / day
Route: oral
Route: multiple
Dose: 30 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
unhealthy, 66 years (range: 25-85 years)
n = 285
Health Status: unhealthy
Condition: secondary hyperparathyroidism
Age Group: 66 years (range: 25-85 years)
Sex: M+F
Population Size: 285
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
Calcium increased serum 4.2%
30 ug 1 times / day multiple, oral (starting)
Dose: 30 ug, 1 times / day
Route: oral
Route: multiple
Dose: 30 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
unhealthy, 66 years (range: 25-85 years)
n = 285
Health Status: unhealthy
Condition: secondary hyperparathyroidism
Age Group: 66 years (range: 25-85 years)
Sex: M+F
Population Size: 285
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
Dyspnea 4.2%
30 ug 1 times / day multiple, oral (starting)
Dose: 30 ug, 1 times / day
Route: oral
Route: multiple
Dose: 30 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
unhealthy, 66 years (range: 25-85 years)
n = 285
Health Status: unhealthy
Condition: secondary hyperparathyroidism
Age Group: 66 years (range: 25-85 years)
Sex: M+F
Population Size: 285
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
Anemia 4.9%
30 ug 1 times / day multiple, oral (starting)
Dose: 30 ug, 1 times / day
Route: oral
Route: multiple
Dose: 30 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
unhealthy, 66 years (range: 25-85 years)
n = 285
Health Status: unhealthy
Condition: secondary hyperparathyroidism
Age Group: 66 years (range: 25-85 years)
Sex: M+F
Population Size: 285
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
Blood creatinine increased 4.9%
30 ug 1 times / day multiple, oral (starting)
Dose: 30 ug, 1 times / day
Route: oral
Route: multiple
Dose: 30 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
unhealthy, 66 years (range: 25-85 years)
n = 285
Health Status: unhealthy
Condition: secondary hyperparathyroidism
Age Group: 66 years (range: 25-85 years)
Sex: M+F
Population Size: 285
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
Nasopharyngitis 4.9%
30 ug 1 times / day multiple, oral (starting)
Dose: 30 ug, 1 times / day
Route: oral
Route: multiple
Dose: 30 ug, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
unhealthy, 66 years (range: 25-85 years)
n = 285
Health Status: unhealthy
Condition: secondary hyperparathyroidism
Age Group: 66 years (range: 25-85 years)
Sex: M+F
Population Size: 285
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP27B1
3

UGT enzymes
27
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
UGT enzymes
27
 likely
CYP27B1
3
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
AHH Chemical co.,ltd
MT-48884
http://www.ahhchemical.com/product/MT-48884.html
Achemtek
0102-017034
http://www.achemtek.com/19356-17-3
ApexBio Technology
B2140
http://www.apexbt.com/calcifediol-26843.html
ApexBio Technology
B1056
http://www.apexbt.com/calcifediol-d6.html
Aurora Fine Chemicals LLC
A17.876.862
http://online.aurorafinechemicals.com/info?ID=A17.876.862
Aurum Pharmatech LLC
W-5159
http://www.Aurumpharmatech.com/Product/ProductDetails/W_5159
AvaChem Scientific
2558
http://www.avachem.com/productSearch.asp?2558
BioCrick
BCC4949
http://www.biocrick.com/Calcifediol-BCC4949.html
BioSynth
W-201718
https://www.biosynth.com/en/products/life-science/other-biochemicals/products/W-201718.html
Boerchem
BC219279
http://www.boerchem.com/?product_36973.html
Capot Chemical
18824
http://www.capotchem.com/en/18824.htm
Capot Chemical
PubChem18824
http://www.capotchem.com/en/18824.htm
Chem Scene
CS-0800
http://www.chemscene.com/19356-17-3.html
ChemFaces
CFN94017
http://www.chemfaces.com/natural/25-Hydroxycholecalciferol-monohydrate-CFN94017.html
ChemMol
44005951
http://www.chemmol.com/chemmol/44005951.html
Chemspace
CSSB00032005042
https://chem-space.com/CSSB00032005042
Chiralblock Biosciences
CB11410
http://www.chiralblock.com/products/63283-36-3.html
EMD Biosciences
679102
http://www.emdbiosciences.com/product/679102
EMD Millipore
679102
http://www.emdbiosciences.com/product/679102
Glentham Life Sciences
GV7732
http://www.glentham.com/products/product/GV7732/
Lab Network
LN00197433
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00197433
MedChem Express
HY-32351
https://www.medchemexpress.com/Calcifediol.html
MuseChem
R028208
https://www.musechem.com/product/R028208.html
OChem
8414
http://www.ocheminc.com/index.php?act=psearch&pid=356C173
Parchem
28428
http://www.parchem.com/chemical-supplier-distributor/Calcifediol-018428.aspx
Selleck Chemicals
S1469
http://www.selleckchem.com/products/Calcifediol.html
Sigma-Aldrich
739642_ALDRICH
https://www.sigmaaldrich.com/catalog/product/aldrich/739642?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
739650_ALDRICH
https://www.sigmaaldrich.com/catalog/product/aldrich/739650?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
739669_ALDRICH
https://www.sigmaaldrich.com/catalog/product/aldrich/739669?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
17938_SIGMA
https://www.sigmaaldrich.com/catalog/product/sigma/17938?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
1086108_USP
https://www.sigmaaldrich.com/catalog/product/usp/1086108?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Tocris
4036
https://www.tocris.com/products/calcifediol_4036
VladaChem
VL273145-10MG
https://www.vladachem.com/product.php?products=19356-17-3
Yuhao Chemical
XJ4467
http://www.chemyuhao.com/19356-17-3.html
abcr GmbH
AB503647
http://www.abcr.com/shop/en/AB503647
abcr GmbH
AB443287
http://www.abcr.de/shop/en/AB443287
eNovation Chemicals
D699759
https://www.enovationchem.com/ProductDetails.asp?ProductID=D699759
eNovation Chemicals
D763693
https://www.enovationchem.com/ProductDetails.asp?ProductID=D763693
eNovation Chemicals
Y0974281
https://www.enovationchem.com/ProductDetails.asp?ProductID=Y0974281
iChemical
EBD2201904
http://www.ichemical.com/products/19356-17-3.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
PubMed

PubMed

TitleDatePubMed
Tubular aggregates in a case of osteomalacic myopathy due to anticonvulsant drugs.
1984 Jan-Feb
1 alpha,25-dihydroxyvitamin D3 inhibits productive infection of human monocytes by HIV-1.
1991 Apr 30
Vitamin D3 compounds regulate human immunodeficiency virus type 1 replication in U937 monoblastoid cells and in monocyte-derived macrophages.
1993 Feb
Calcidiol and PTH levels in women attending an osteoporosis program.
1999 Apr
Kidney microsomal 25- and 1alpha-hydroxylase in vitamin D metabolism: catalytic properties, molecular cloning, cellular localization and expression during development.
2002 Feb 28
Androgen enhances the antiproliferative activity of vitamin D3 by suppressing 24-hydroxylase expression in LNCaP cells.
2006 Apr
Vitamin D metabolism in human prostate cells: implications for prostate cancer chemoprevention by vitamin D.
2006 Jul-Aug
Patents

Patents

JP4806519B2
14
JPH0586021A
3
JPS62263110A
3

Sample Use Guides

In Vivo Use Guide
The initial dose of RAYALDEE (calcifediol) extended-release capsules is 30 mcg administered orally once daily at bedtime. Serum calcium should be below 9.8 mg/dL before initiating treatment. Monitor serum calcium, phosphorus, 25-hydroxyvitamin D and intact parathyroid hormone (PTH) 3 months after starting therapy or changing dose. Increase the dose to 60 mcg once daily after 3 months if intact PTH is above the treatment goal. Ensure serum calcium is below 9.8 mg/dL, phosphorus is below 5.5 mg/dL and 25-hydroxyvitamin D is below 100 ng/mL before increasing the dose. Suspend dosing if intact PTH is persistently abnormally low, serum calcium is consistently above the normal range or serum 25­ hydroxyvitamin D is consistently above 100 ng/mL
Route of Administration: Oral
In Vitro Use Guide
Vitamin D metabolites down-regulated stimulated IL-8 only in those hyperinflammatory monocyte-derived macrophages, and only when used at high doses (>100 nM for Calcifediol).
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:03:42 UTC 2023
Edited
by admin
on Fri Dec 15 16:03:42 UTC 2023
Record UNII
P6YZ13C99Q
Record Status Validated (UNII)
Record Version
  • Download
Related Record Type
Name Type Language
CALCIFEDIOL
EP   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN  
Official Name English
CALCIFEDIOL [VANDF]
Common Name English
U-32070E
Code English
HIDROFEROL
Brand Name English
DIDROGYL
Brand Name English
CALCIFEDIOL [EP IMPURITY]
Common Name English
CALCIFEDIOL [ORANGE BOOK]
Common Name English
CALCIFEDIOL HYDRATE
Common Name English
CALCIFEDIOL [USAN]
Common Name English
U-32,070E
Code English
9,10-Secocholesta-5,7,10(19)-triene-3,25-diol, monohydrate, (3β,5Z,7E)-
Systematic Name English
25-Hydroxycholecalciferol monohydrate
Common Name English
1H-Indene-1-pentanol, 4-[(2Z)-2-[(5S)-5-hydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-α,α,ε,7a-tetramethyl-, hydrate (1:1), (εR,1R,3aS,4E,7aR)-
Systematic Name English
CALCIFEDIOL [USP-RS]
Common Name English
Calcifediol monohydrate [WHO-DD]
Common Name English
CALDEROL
Brand Name English
CALCIFEDIOL [USP MONOGRAPH]
Common Name English
Calcifediol [WHO-DD]
Common Name English
Classification Tree Code System Code
LIVERTOX 138
Created by admin on Fri Dec 15 16:03:43 UTC 2023 , Edited by admin on Fri Dec 15 16:03:43 UTC 2023
NCI_THESAURUS C39713
Created by admin on Fri Dec 15 16:03:43 UTC 2023 , Edited by admin on Fri Dec 15 16:03:43 UTC 2023
WHO-ATC A11CC06
Created by admin on Fri Dec 15 16:03:43 UTC 2023 , Edited by admin on Fri Dec 15 16:03:43 UTC 2023
WHO-VATC QA11CC06
Created by admin on Fri Dec 15 16:03:43 UTC 2023 , Edited by admin on Fri Dec 15 16:03:43 UTC 2023
Code System Code Type Description
FDA UNII
P6YZ13C99Q
Created by admin on Fri Dec 15 16:03:43 UTC 2023 , Edited by admin on Fri Dec 15 16:03:43 UTC 2023
PRIMARY
DRUG BANK
DBSALT002443
Created by admin on Fri Dec 15 16:03:43 UTC 2023 , Edited by admin on Fri Dec 15 16:03:43 UTC 2023
PRIMARY
DAILYMED
P6YZ13C99Q
Created by admin on Fri Dec 15 16:03:43 UTC 2023 , Edited by admin on Fri Dec 15 16:03:43 UTC 2023
PRIMARY
PUBCHEM
6441383
Created by admin on Fri Dec 15 16:03:43 UTC 2023 , Edited by admin on Fri Dec 15 16:03:43 UTC 2023
PRIMARY
SMS_ID
300000038170
Created by admin on Fri Dec 15 16:03:43 UTC 2023 , Edited by admin on Fri Dec 15 16:03:43 UTC 2023
PRIMARY
RXCUI
1889
Created by admin on Fri Dec 15 16:03:43 UTC 2023 , Edited by admin on Fri Dec 15 16:03:43 UTC 2023
PRIMARY RxNorm
ChEMBL
CHEMBL1040
Created by admin on Fri Dec 15 16:03:43 UTC 2023 , Edited by admin on Fri Dec 15 16:03:43 UTC 2023
PRIMARY
DRUG CENTRAL
464
Created by admin on Fri Dec 15 16:03:43 UTC 2023 , Edited by admin on Fri Dec 15 16:03:43 UTC 2023
PRIMARY
WIKIPEDIA
CALCIFEDIOL
Created by admin on Fri Dec 15 16:03:43 UTC 2023 , Edited by admin on Fri Dec 15 16:03:43 UTC 2023
PRIMARY
CAS
63283-36-3
Created by admin on Fri Dec 15 16:03:43 UTC 2023 , Edited by admin on Fri Dec 15 16:03:43 UTC 2023
PRIMARY
NCI_THESAURUS
C65278
Created by admin on Fri Dec 15 16:03:43 UTC 2023 , Edited by admin on Fri Dec 15 16:03:43 UTC 2023
PRIMARY
CHEBI
17933
Created by admin on Fri Dec 15 16:03:43 UTC 2023 , Edited by admin on Fri Dec 15 16:03:43 UTC 2023
PRIMARY
MESH
D002112
Created by admin on Fri Dec 15 16:03:43 UTC 2023 , Edited by admin on Fri Dec 15 16:03:43 UTC 2023
PRIMARY
RS_ITEM_NUM
1086108
Created by admin on Fri Dec 15 16:03:43 UTC 2023 , Edited by admin on Fri Dec 15 16:03:43 UTC 2023
PRIMARY
Related Record Type Details
Structure of CALCIFEDIOL ANHYDROUS
ANHYDROUS->SOLVATE
VITAMIN D3 RECEPTOR
TARGET -> AGONIST
CTAP-101
SUB_CONCEPT->SUBSTANCE
Structure of CALCIFEDIOL ANHYDROUS
PARENT -> SALT/SOLVATE
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Related Record Type Details
Structure of 25-HYDROXYTACHYSTEROL 3
IMPURITY -> PARENT
Structure of 25-HYDROXY-7-DEHYDROCHOLESTEROL
IMPURITY -> PARENT
Structure of (3β,9β,10α)-Cholesta-5,7-diene-3,25-diol
IMPURITY -> PARENT
Structure of 25-HYDROXYCHOLECALCIFEROL, 5-TRANS-
IMPURITY -> PARENT
Related Record Type Details
Structure of CALCIFEDIOL ANHYDROUS
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966